Augtyro

Generic name: repotrectinib

Used for: Advanced ROS1-positive non-small cell lung cancer · Advanced solid tumors with an NTRK gene fusion · 1 more

How do you pay?

How to pay the least

Ask for the cash price

Augtyro

We didn’t find one.

  1. Ask your pharmacy for Augtyro’s cash price, and one or two other pharmacies too.
  2. Augtyro’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bristol Myers Squibb Patient Assistance Foundation (BMSPAF). Or call 1-800-736-0003.

See if you qualify 

Compare every option

Question
Brand nameAugtyro
Authorized genericrepotrectinib
Regular genericrepotrectinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Augtyro?
The original
–
–

Brand nameThe maker’s card

BMS Access Support Co-Pay Assistance Program

Savings card from Bristol Myers Squibb

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a month

Sign up on bmsaccesssupport.com 

Or call 1-800-861-0048.

In the maker’s words

“$0 Co-pay per one-month supply…”

From the maker’s offer on bmsaccesssupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Augtyro itself, from the same company, sold without the brand name, and usually for less. For now Augtyro is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

AUGTYRO is a kinase inhibitor indicated for the treatment of

  • adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
  • adult and pediatric patients 12 years of age and older with solid tumors that:
  • have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and
  • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.
  • have progressed following treatment or have no satisfactory alternative therapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Source: the FDA label for Augtyro (E.R. Squibb & Sons, L.L.C.), June 13, 2024. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/augtyro/